Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great…
In Conversation
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how…
Promega is a truly global company with a vast international presence. What would you say is the strategic importance that the Benelux affiliate has assumed within…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed the evolution of the OTC market from…
Medichem began production at its plant in Malta in 2006. Can you give us a brief overview of the facilities, and of the importance of the…
The society started at the beginning of the 20th century with the combination of the Penang Pharmaceutical Association and the Straits Pharmaceutical Association. Have there been…
Would you begin by giving our readers a brief overview of the recent changes in the Ministry of Health’s focus? After Prime Minister Najib changed Malaysia’s…
How would you describe MABIC today and the way that it has evolved since its creation in 2000? The Malaysian Biotech Information Centre or MABIC is…
Actavis’ Maltese operations began as far back as 1976 as a different company ( Pharmamed Ltd.). In 2001, this Malta facility was acquired by Actavis which…
Can you give us a brief description of Metallform’s activity since the establishment of the Maltese subsidiary in 1992? The parent company Metallform GmbH & Cokg…
